clinical trial · NCT05067478
Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
Urovant Sciences GmbH·—·completed·n = 403
Overactive BladderVibegron
brief summary
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.
started
Oct 28, 2021
primary completion
Jul 22, 2024
completion
Jul 26, 2024
last updated
Dec 27, 2024
official title
Composur, a Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol